Reprogramming Healthspan

We're building the next generation of therapies that address cancer and aging at their common source — epigenetic damage.

What does 199 Bio do?

199 Biotechnologies pioneers breakthrough therapies using partial reprogramming and cancer reprogramming to restore cellular youth and modify cancer cell behavior through controlled epigenetic changes. We're developing first-in-class cancer treatments using transcription factors to reduce tumor aggressiveness, accessible longevity diagnostics that cost 10x less than traditional labs, and senolytic polyphenol compounds — all based on reprogramming cells at the epigenetic level rather than destroying them.

The dual crisis we face

Cancer remains intractable

< 5%

Glioblastoma 5-year survival rate

Despite decades of research, surgery, radiation and chemotherapy extend life by mere months for the deadliest cancers.

Aging accelerates globally

2.1B

People over 60 by 2050

86% of adults over 65 already live with chronic disease, while healthcare systems strain under the burden.

Both crises share a root cause: epigenetic damage that locks cells into malignant or dysfunctional states.

Our breakthrough insight

Cells aren't permanently broken — they're locked in the wrong program. We can guide them back.

Epigenetic Reset

Brief exposure to our proprietary reprogramming factors can restore youthful cellular function

Precision Targeting

Cancer cells and senescent cells can be selectively addressed without influencing surrounding healthy cells

Measurable Impact

Targeting epigenetic changes results in significant impact in outcome with clear measurable markers

Three programs, one mission

Each program attacks aging and disease from a different angle, creating a comprehensive platform for healthspan extension.

Partial Reprogramming

Lead Program

Revolutionary cancer therapy that uses epigenetic reprogramming to completely rewrite cancer cell behavior — halting metastasis, invasion, and growth before triggering programmed cell death.

Why this matters

Our epigenetic approach completely rewrites cancer cell behavior, overcoming drug resistance and eliminating cancer stem cells. This transformation halts invasion and growth before triggering the cell's own death mechanisms — the final hara-kiri moment.

Current status

E-ON-001 (GBM lead) in preclinical efficacy studies. Two backup candidates in development.

Senolytic Research

100+ Compounds

Safe interventions and supplements that remove senescent cells, delivering healthspan benefits you can access today.

Why this matters

We've screened and synthesized over 100 senolytic compounds to find those that are both effective and safe for regular use.

Current status

PCC1 lead formulation in optimization. Multiple compounds in pipeline.

Longevity Diagnostics

Next Day Results

Reliable, accessible, low-cost biomarker testing that gives you control over your health trajectory.

Why this matters

You can't improve what you can't measure. We make comprehensive healthspan tracking as easy as ordering a blood test.

Current status

AgeQuant™ platform live. NAD+, senescence markers, microplastics, and more.

Frequently Asked Questions

What is partial reprogramming?

What is cancer reprogramming?

How does 199 Biotechnologies approach cancer differently?

What is AgeQuant and how does it work?

What is Boris Djordjevic's background in biotechnology?

How can I access 199 Bio's treatments?

What makes Procyanidin C1 special for longevity?

Our moonshot

If we can reprogram glioblastoma — the deadliest brain cancer — we can transform how humanity approaches cancer. This breakthrough paves the way for epigenetic therapies to address broader conditions like neurodegenerative diseases, frailty, autoimmune conditions, vision loss, and even skin appearance.